Isothermal Microcalorimetry as a Quality by Design Tool to Determine Optimal Blending Sequences
Journal Title: The AAPS Journal - Year 2010, Vol 12, Issue 3
Abstract
This study was designed to assess the value of isothermal microcalorimetry (ITMC) as a quality by design (QbD) tool to optimize blending conditions during tablet preparation. Powder mixtures that contain microcrystalline cellulose (MCC), dibasic calcium phosphate dihydrate (DCPD), and prednisone were prepared as 1:1:1 ratios using different blending sequences. ITMC was used to monitor the thermal activity of the powder mixtures before and after each blending process. Differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) were performed on all final powder mixtures. Final powder mixtures were used to prepare tablets with 10 mg prednisone content, and dissolution tests were performed on all tablet formulations. Using ITMC, it was observed that the powder mixtures had different thermal activity depending on the blending sequences of the ingredients. All mixtures prepared by mixing prednisone with DCPD in the first stage were associated with relatively fast and significant heat exchange. In contrast, mixing prednisone with MCC in the first step resulted in slower heat exchange. Powder mixture with high thermal activity showed extra DSC peaks, and their dissolution was generally slower compared to the other tablets. Blending is considered as a critical parameter in tablet preparation. This study showed that ITMC is a simple and efficient tool to monitor solid-state reactions between excipients and prednisone depending on blending sequences. ITMC has the potential to be used in QbD approaches to optimize blending parameters for prednisone tablets.
Authors and Affiliations
M. H. D. Kamal Al-Hallak, Shirzad Azarmi, Zhenghe Xu, Yadollah Maham, Raimar Löbenberg
Keywords
Related Articles
- EP ID EP681392
- DOI 10.1208/s12248-010-9202-4
- Views 80
- Downloads 0
Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
CT-P13, the world’s first biosimilar monoclonal antibody to infliximab, was approved for marketing in South Korea for all the six indications of infliximab, which Europe may follow, although the product was teste...
Characterization of the humanMDR1 gene
P-glycoprotein (Pgp), an ATP-dependent efflux transporter that protects the body from environmental toxins and xenobiotics, is encoded by the humanMDR1 gene. HumanMDR1 is located on chromosomal region 7q21. Although seve...
Amphiphilic star-like macromolecules as novel carriers for topical delivery of nonsteroidal anti-inflammatory drugs
The objective of this study was to evaluate amphiphilic star-like macromolecules (ASMs) as a topical drug delivery system. Indomethacin, piroxicam, and ketoprofen were individually encapsulated into the ASMs using coprec...
Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants
There are similar challenges in developing a product designed to treat patients with a rare disease and drugs to treat critically ill neonates and infants. Part of the challenge in developing such products as well as ide...
Factors Influencing Magnitude and Duration of Target Inhibition Following Antibody Therapy: Implications in Drug Discovery and Development
Antibodies or antibody-related fusion proteins binding to soluble antigens in plasma form an important subclass of approved therapeutics. Pharmaceutical companies are constantly trying to accelerate the pace of drug disc...